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[etter  to  the  editor
etter on the article “Malignant head/neck
aragangliomas. Comparative study”
orrespondance à propos de l’article : « Histoire naturelle des paragan-
liomes malins de la tête et du cou. Analyse comparative »
o Editor,
Mediouni et al. [1], in their recent article, described their experi-
nce in the treatment of malignant head and neck paragangliomas
HNPs) and, in particular, compared the epidemiological, clinical
nd genetic characteristics, natural history and treatment with
hose of a series of 131 benign HNPs. We  congratulate the authors
or the interesting manuscript that offers many opportunities for
urther research.
Approximately 10% to 15% of HNP cases are familial. The major-
ty of these cases are caused by mutations in SDHB or SDHD with
utations in SDHC occurring less commonly [2]. The occurrence of
alignancy is also signiﬁcantly different in sporadic and familial
ases. Its overall frequency is reported to be 2 to 5% for jugulo-
ympanic paragangliomas, 6% for carotid body and between 16 and
9% for glomus vagale tumours [3]. Surgery is recommended for all
atients, if they are in good general health and a global evaluation
oes not provide data for its contraindication [4]. The incidence
f tumour recurrence in the follow-up ranges from 3 to 20% [5].
e agree with the authors that familial cases and SDHB mutations
re more frequently associated with malignancy and the risk of
ecurrence.
Currently, the study protocol of HNPs requires the use of
uclear medicine. The same authors have used 111In-pentetreotide
cintigraphy (Octreoscan), 18F-Fluorodeoxyglucose-Positron Emis-
ion Tomography (18F-FDG-PET) or 123I-MIBG scintigraphy, but
one of these methods has proved to be sufﬁciently sensitive to
etect the presence of bone metastases. Do you think that the use
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879-7296/© 2014 Elsevier Masson SAS. All rights reserved.of MRI  should become of choice in these patients? How frequently
should be performed?
In addition, the authors describe a metastatic disease at diag-
nosis in 3 patients and during follow-up in the other 8 patients.
The prognosis was worse in patients with liver metastases. Do  you
think that it was just a coincidence?
Finally, the authors correctly state that no consensus has been
reached concerning the histological criteria of malignancy (multi-
ple mitotic ﬁgures, nuclear polymorphism and capsular effraction).
We observed in our experience a correlation between malignancy
and the presence of metastasis and recurrence rate. Have you
observed this correlation?
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